http://www.laboratorytalk.com/news/ofo/ofo000.html Oxford BioMedica news releases on Laboratorytalk en-gb Copyright (C)2008 Pro-Talk Ltd. All rights reserved. Mon, 14 Jul 2008 08:00:00 UT Mon, 14 Jul 2008 08:00:00 UT http://www.pro-talk.com/images/protalklogo90.gif http://www.pro-talk.com/ 90 79 The rights granted are exclusive for RNAi gene silencing using lentiviral vector technology for human gene therapy applications, including Oxford BioMedica's proprietary LentiVector system Tue, 08 Jan 2008 08:00:00 UT Oxford BioMedica http://www.laboratorytalk.com/news/ofo/ofo189.html Oxford BioMedica and Sanofi-Aventis have entered into an exclusive global licensing agreement to develop and commercialise Trovax for the treatment and prevention of cancers Thu, 29 Mar 2007 08:00:00 UT Oxford BioMedica http://www.laboratorytalk.com/news/ofo/ofo188.html Acquisition of privately held biotechnology company, based in Oxford, UK, adds melanoma cancer vaccine and extends immunotherapy platform Tue, 13 Mar 2007 08:00:00 UT Oxford BioMedica http://www.laboratorytalk.com/news/ofo/ofo187.html Oxford BioMedica, Viragen , and Roslin Institute, announce the successful expression of human interferon alpha-2a in the whites of eggs laid by transgenic hens using the Ova system Thu, 25 Jan 2007 08:00:00 UT Oxford BioMedica http://www.laboratorytalk.com/news/ofo/ofo186.html PNAS has published an article profiling the avian transgenic (Ova) system's ability to express two therapeutic proteins in the whites of eggs of transgenic hens Wed, 17 Jan 2007 08:00:00 UT Oxford BioMedica http://www.laboratorytalk.com/news/ofo/ofo185.html Oxford BioMedica reports that the Phase III Trist trial of its novel cancer immunotherapy, TroVax, in patients with renal cancer, has been adopted by the UK National Cancer Research Network (NCRN) Thu, 11 Jan 2007 08:00:00 UT Oxford BioMedica http://www.laboratorytalk.com/news/ofo/ofo184.html Oxford BioMedica and Sigma-Aldrich have signed a joint licence agreement for LentiVector technology with GlaxoSmithKline (GSK), which provides GSK with access to the technology for research activities Mon, 25 Dec 2006 08:00:00 UT Oxford BioMedica http://www.laboratorytalk.com/news/ofo/ofo183.html Oxford BioMedica has expanded an existing licence agreement for its LentiVector technology with a major multinational pharmaceutical company Wed, 20 Dec 2006 08:00:00 UT Oxford BioMedica http://www.laboratorytalk.com/news/ofo/ofo182.html Oxford BioMedica's Trovax receives positive recommendation for orphan drug designation in renal cancer from EMEA Mon, 11 Dec 2006 08:00:00 UT Oxford BioMedica http://www.laboratorytalk.com/news/ofo/ofo181.html Preclinical efficacy results with gene-based product for Parkinson's disease, ProSavin, were presented at 14th Annual Congress of the European Society of Gene Therapy (ESGT) in Athens, November 2006 Thu, 16 Nov 2006 08:00:00 UT Oxford BioMedica http://www.laboratorytalk.com/news/ofo/ofo179.html RCC trials are designed to evaluate the safety, immunogenicity and effectiveness of TroVax as a single agent and in combination with standard therapy of interleukin-2 (IL-2) or interferon-a (IFN) Thu, 16 Nov 2006 08:00:00 UT Oxford BioMedica http://www.laboratorytalk.com/news/ofo/ofo180.html Oxford BioMedica says the first patient has been treated in Trist, a multi-centre Phase III trial of cancer immunotherapy TroVax in patients with advanced or metastatic renal cell carcinoma (RCC) Wed, 08 Nov 2006 08:00:00 UT Oxford BioMedica http://www.laboratorytalk.com/news/ofo/ofo178.html Oxford BioMedica has presented further 'encouraging' data from six Phase II trials of TroVax, at the 14th International Cancer Immunotherapy Meeting, 4-6 October 2006 in New York City Mon, 09 Oct 2006 08:00:00 UT Oxford BioMedica http://www.laboratorytalk.com/news/ofo/ofo177.html Oxford Biomedica expands its ocular programme through collaboration and investment led by the Foundation Fighting Blindness Tue, 03 Oct 2006 08:00:00 UT Oxford BioMedica http://www.laboratorytalk.com/news/ofo/ofo176.html Regulatory clearance for start of patient recruitment in 120-patient Phase II trial of TroVax in patients with late-stage breast cancer Wed, 06 Sep 2006 08:00:00 UT Oxford BioMedica http://www.laboratorytalk.com/news/ofo/ofo175.html Principal Investigator for TroVax Phase II trials to present at Cancer Immunotherapuetics and Vaccines meeting in Cambridge, Massachusetts, on 22-23 August 2006 Tue, 22 Aug 2006 08:00:00 UT Oxford BioMedica http://www.laboratorytalk.com/news/ofo/ofo174.html